Revenue Summary of Adhera Therapeutics, Inc.

Adhera Therapeutics, Inc.'s latest annual revenue in 2022 was - USD , down 0.0% from previous year.
Adhera Therapeutics, Inc.'s latest quarterly revenue in 2023 Q3 was - USD , down 0.0% from previous quarter.
Adhera Therapeutics, Inc. reported a annual revenue of - USD in annual revenue 2021, down 0.0% from previous year.
Adhera Therapeutics, Inc. reported a annual revenue of - USD in annual revenue 2020, down -100.0% from previous year.
Adhera Therapeutics, Inc. reported a quarterly revenue of - USD for 2023 Q3, down 0.0% from previous quarter.
Adhera Therapeutics, Inc. reported a quarterly revenue of - USD for 2023 Q2, down 0.0% from previous quarter.

Annual Revenue Chart of Adhera Therapeutics, Inc. (2022 - 1989)

Historical Annual Revenue of Adhera Therapeutics, Inc. (2022 - 1989)

Year	Revenue	Revenue Growth
2022	- USD	0.0%
2021	- USD	0.0%
2020	- USD	-100.0%
2019	252 Thousand USD	230.77%
2018	76.18 Thousand USD	0.0%
2017	- USD	0.0%
2016	- USD	-100.0%
2015	680 Thousand USD	36.0%
2014	500 Thousand USD	-76.36%
2013	2.11 Million USD	-49.85%
2012	4.21 Million USD	88.6%
2011	2.23 Million USD	-9.11%
2010	2.46 Million USD	-83.3%
2009	14.73 Million USD	464.66%
2008	2.6 Million USD	-85.62%
2007	18.13 Million USD	-36.34%
2006	28.49 Million USD	282.47%
2005	7.44 Million USD	303.3%
2004	1.84 Million USD	-90.5%
2003	19.44 Million USD	117.86%
2002	8.92 Million USD	242.8%
2001	2.6 Million USD	-37.14%
2000	4.14 Million USD	-7.98%
1999	4.5 Million USD	-44.44%
1998	8.1 Million USD	97.56%
1997	4.1 Million USD	0.0%
1996	- USD	-100.0%
1995	2.9 Million USD	38.1%
1994	2.1 Million USD	144.19%
1993	860 Thousand USD	168.75%
1992	320 Thousand USD	-57.89%
1991	760 Thousand USD	-36.13%
1990	1.19 Million USD	85.94%
1989	640 Thousand USD	77.78%

Year	Revenue	Revenue Growth
2023 Q1	- USD	0.0%
2023 Q3	- USD	0.0%
2023 Q2	- USD	0.0%
2022 Q4	- USD	0.0%
2022 Q1	- USD	0.0%
2022 Q2	- USD	0.0%
2022 Q3	- USD	0.0%
2022 FY	- USD	0.0%
2021 Q1	- USD	0.0%
2021 Q3	- USD	0.0%
2021 Q2	- USD	0.0%
2021 FY	- USD	0.0%
2021 Q4	- USD	0.0%
2020 Q1	- USD	-100.0%
2020 FY	- USD	-100.0%
2020 Q2	- USD	0.0%
2020 Q3	- USD	0.0%
2020 Q4	- USD	0.0%
2019 Q1	2881.00 USD	4983.05%
2019 Q3	51 Thousand USD	-22.73%
2019 FY	252 Thousand USD	230.77%
2019 Q4	132 Thousand USD	158.82%
2019 Q2	66 Thousand USD	2190.87%
2018 Q2	- USD	0.0%
2018 Q4	-59.00 USD	-100.08%
2018 Q3	76.18 Thousand USD	0.0%
2018 Q1	- USD	100.0%
2018 FY	76.18 Thousand USD	0.0%
2017 Q2	- USD	0.0%
2017 FY	- USD	0.0%
2017 Q4	-127.93 Thousand USD	0.0%
2017 Q1	- USD	100.0%
2017 Q3	- USD	0.0%
2016 Q1	250 Thousand USD	25.0%
2016 Q4	-300 Thousand USD	-700.0%
2016 Q3	50 Thousand USD	0.0%
2016 FY	- USD	-100.0%
2016 Q2	- USD	-100.0%
2015 Q2	400 Thousand USD	0.0%
2015 FY	680 Thousand USD	36.0%
2015 Q3	80 Thousand USD	-80.0%
2015 Q1	- USD	-100.0%
2015 Q4	200 Thousand USD	150.0%
2014 FY	500 Thousand USD	-76.36%
2014 Q4	500 Thousand USD	0.0%
2014 Q3	- USD	0.0%
2014 Q2	- USD	0.0%
2014 Q1	- USD	-100.0%
2013 Q2	315 Thousand USD	0.0%
2013 FY	2.11 Million USD	-49.85%
2013 Q4	1 Million USD	25.0%
2013 Q3	800 Thousand USD	153.97%
2013 Q1	- USD	-100.0%
2012 Q1	131 Thousand USD	-91.85%
2012 FY	4.21 Million USD	88.6%
2012 Q4	1.32 Million USD	19.53%
2012 Q3	1.1 Million USD	-33.29%
2012 Q2	1.65 Million USD	1165.65%
2011 FY	2.23 Million USD	-9.11%
2011 Q1	214 Thousand USD	-77.54%
2011 Q2	129 Thousand USD	-39.72%
2011 Q3	286 Thousand USD	121.71%
2011 Q4	1.6 Million USD	461.89%
2010 Q4	953 Thousand USD	-15.66%
2010 Q3	1.13 Million USD	485.49%
2010 Q2	193 Thousand USD	4.89%
2010 FY	2.46 Million USD	-83.3%
2010 Q1	184 Thousand USD	-11.54%
2009 Q4	208 Thousand USD	225.0%
2009 Q1	14.15 Million USD	7467.38%
2009 Q3	64 Thousand USD	-79.29%
2009 Q2	309 Thousand USD	-97.82%
2009 FY	14.73 Million USD	464.66%
2008 Q3	405 Thousand USD	-46.29%
2008 Q1	1.26 Million USD	-80.23%
2008 FY	2.6 Million USD	-85.62%
2008 Q2	754 Thousand USD	-40.3%
2008 Q4	187 Thousand USD	-53.83%
2007 Q4	6.38 Million USD	236.74%
2007 Q3	1.89 Million USD	-60.97%
2007 FY	18.13 Million USD	-36.34%
2007 Q2	4.86 Million USD	-2.64%
2007 Q1	4.99 Million USD	3.65%
2006 FY	28.49 Million USD	282.47%
2006 Q4	4.81 Million USD	-13.15%
2006 Q1	6.71 Million USD	419.17%
2006 Q2	11.41 Million USD	69.86%
2006 Q3	5.54 Million USD	-51.41%
2005 FY	7.44 Million USD	303.3%
2005 Q3	1.22 Million USD	-23.66%
2005 Q4	1.29 Million USD	5.81%
2005 Q2	1.6 Million USD	-51.89%
2005 Q1	3.33 Million USD	129.5%
2004 FY	1.84 Million USD	-90.5%
2004 Q4	1.45 Million USD	614.78%
2004 Q3	203 Thousand USD	351.11%
2004 Q2	45 Thousand USD	-69.59%
2004 Q1	148 Thousand USD	-83.75%
2003 Q4	911 Thousand USD	84.41%
2003 FY	19.44 Million USD	117.86%
2003 Q1	2.31 Million USD	31.87%
2003 Q3	494 Thousand USD	-96.86%
2003 Q2	15.71 Million USD	578.38%
2002 Q1	1.52 Million USD	370.68%
2002 Q2	3.65 Million USD	139.74%
2002 Q3	1.98 Million USD	-45.71%
2002 Q4	1.75 Million USD	-11.49%
2002 FY	8.92 Million USD	242.8%
2001 FY	2.6 Million USD	-37.14%
2001 Q2	753 Thousand USD	-15.68%
2001 Q4	324 Thousand USD	-59.95%
2001 Q3	809 Thousand USD	7.44%
2001 Q1	893 Thousand USD	-30.45%
2000 FY	4.14 Million USD	-7.98%
2000 Q2	815 Thousand USD	-7.6%
2000 Q1	882 Thousand USD	-11.8%
2000 Q3	1.16 Million USD	42.33%
2000 Q4	1.28 Million USD	10.69%
1999 Q4	1 Million USD	0.0%
1999 Q1	1.4 Million USD	27.27%
1999 Q2	1.1 Million USD	-21.43%
1999 Q3	1 Million USD	-9.09%
1999 FY	4.5 Million USD	-44.44%
1998 Q3	2.1 Million USD	-25.0%
1998 Q2	2.8 Million USD	33.33%
1998 Q1	2.1 Million USD	90.91%
1998 Q4	1.1 Million USD	-47.62%
1998 FY	8.1 Million USD	97.56%
1997 Q3	1 Million USD	-9.09%
1997 FY	4.1 Million USD	0.0%
1997 Q4	1.1 Million USD	10.0%
1997 Q2	1.1 Million USD	37.5%
1997 Q1	800 Thousand USD	0.0%
1996 Q2	1.4 Million USD	40.0%
1996 Q1	1 Million USD	42.86%
1996 Q3	1.1 Million USD	-21.43%
1996 FY	- USD	-100.0%
1995 Q2	1 Million USD	42.86%
1995 Q1	700 Thousand USD	16.67%
1995 Q3	800 Thousand USD	-20.0%
1995 Q4	700 Thousand USD	-12.5%
1995 FY	2.9 Million USD	38.1%
1994 Q2	700 Thousand USD	40.0%
1994 Q3	700 Thousand USD	0.0%
1994 FY	2.1 Million USD	144.19%
1994 Q4	600 Thousand USD	-14.29%
1994 Q1	500 Thousand USD	25.0%
1993 Q3	500 Thousand USD	31.58%
1993 FY	860 Thousand USD	168.75%
1993 Q4	400 Thousand USD	-20.0%
1993 Q2	380 Thousand USD	0.0%
1992 FY	320 Thousand USD	-57.89%
1991 FY	760 Thousand USD	-36.13%
1990 FY	1.19 Million USD	85.94%
1989 FY	640 Thousand USD	77.78%

Peer Revenue Comparison of Adhera Therapeutics, Inc.

Name	Revenue	Revenue Difference
Burzynski Research Institute, Inc.	- USD	NaN%
Arch Therapeutics, Inc.	75.72 Thousand USD	100.0%
Evofem Biosciences, Inc.	18.21 Million USD	100.0%
Nascent Biotech, Inc.	- USD	NaN%
Rebus Holdings, Inc.	- USD	NaN%
Santhera Pharmaceuticals Holding AG	122.95 Million USD	100.0%
Qrons Inc.	- USD	NaN%
Adynxx, Inc.	- USD	NaN%
Neon Bloom, Inc.	- USD	NaN%
Northwest Biotherapeutics, Inc.	1.93 Million USD	100.0%
ProtoKinetix, Incorporated	- USD	NaN%
Skye Bioscience, Inc.	- USD	NaN%
Eiger BioPharmaceuticals, Inc.	15.77 Million USD	100.0%
Nanobac Pharmaceuticals, Incorporated	17.62 Thousand USD	100.0%
Institute of Biomedical Research Corp.	- USD	NaN%
SQZ Biotechnologies Company	21.47 Million USD	100.0%
Intellipharmaceutics International Inc.	65.72 Thousand USD	100.0%
Propanc Biopharma, Inc.	- USD	NaN%
Mesoblast Limited	5.9 Million USD	100.0%
Marizyme, Inc.	645.81 Thousand USD	100.0%
Genus plc	668.8 Million USD	100.0%
VioQuest Pharmaceuticals, Inc.	- USD	NaN%
Pharming Group N.V.	245.31 Million USD	100.0%
Therapeutic Solutions International, Inc.	98.99 Thousand USD	100.0%
CNBX Pharmaceuticals Inc.	410.16 Thousand USD	100.0%
Nymox Pharmaceutical Corporation	- USD	NaN%
ContraFect Corporation	- USD	NaN%
PsyBio Therapeutics Corp.	- USD	NaN%
Sienna Biopharmaceuticals, Inc.	- USD	NaN%
RegeneRx Biopharmaceuticals, Inc.	76.76 Thousand USD	100.0%
IMV Inc.	- USD	NaN%
AXIM Biotechnologies, Inc.	39.51 Thousand USD	100.0%
MultiCell Technologies, Inc.	49.32 USD	100.0%
ONE Bio Corp.	52.29 Million USD	100.0%
Accustem Sciences Inc.	- USD	NaN%
RVL Pharmaceuticals plc	49.72 Million USD	100.0%
Arno Therapeutics, Inc.	- USD	NaN%
EV Biologics, Inc.	48.9 Thousand USD	100.0%
Q BioMed Inc.	284.35 Thousand USD	100.0%
Emmaus Life Sciences, Inc.	29.59 Million USD	100.0%
Mosaic ImmunoEngineering Inc.	- USD	NaN%
Biomind Labs Inc.	- USD	NaN%
American Oriental Bioengineering, Inc.	145.09 Million USD	100.0%
Provectus Biopharmaceuticals, Inc.	557.71 Thousand USD	100.0%
TetraLogic Pharmaceuticals Corporation	- USD	NaN%
Oncotelic Therapeutics, Inc.	70 Thousand USD	100.0%
GlobeStar Therapeutics Corporation	- USD	NaN%
THC Farmaceuticals, Inc.	- USD	NaN%
Acro Biomedical Co., Ltd.	658.5 Thousand USD	100.0%
Curative Biotechnology, Inc.	- USD	NaN%
GB Sciences, Inc.	- USD	NaN%
Alpha Cognition Inc.	- USD	NaN%
HST Global, Inc.	- USD	NaN%
CSL Limited	14.69 Billion USD	100.0%
Wesana Health Holdings Inc.	- USD	NaN%
Halberd Corporation	999.00 USD	100.0%
Enzolytics Inc.	52.79 Thousand USD	100.0%
Agentix Corp.	- USD	NaN%
Resverlogix Corp.	- USD	NaN%
Nuo Therapeutics, Inc.	608.52 Thousand USD	100.0%
MetaStat, Inc.	- USD	NaN%
argenx SE	1.22 Billion USD	100.0%
Enzon Pharmaceuticals, Inc.	- USD	NaN%
Endonovo Therapeutics, Inc.	140.24 Thousand USD	100.0%
RespireRx Pharmaceuticals Inc.	- USD	NaN%
GeneThera, Inc.	- USD	NaN%
Inhibitor Therapeutics, Inc.	- USD	NaN%
AVAX Technologies, Inc.	617.38 Thousand USD	100.0%
Zenith Capital Corp.	- USD	NaN%
Genscript Biotech Corporation	839.52 Million USD	100.0%
Ember Therapeutics, Inc.	- USD	NaN%
Anthera Pharmaceuticals, Inc.	- USD	NaN%
Sigyn Therapeutics, Inc.	- USD	NaN%
WPD Pharmaceuticals Inc.	- USD	NaN%
Cotinga Pharmaceuticals Inc.	- USD	NaN%
Kadimastem Ltd	- USD	NaN%
Helix BioMedix, Inc.	997.72 Thousand USD	100.0%
VitaSpring Biomedical Co. Ltd.	- USD	NaN%
Capstone Therapeutics Corp.	48.35 Million USD	100.0%
BioStem Technologies, Inc.	16.68 Million USD	100.0%
Oncology Pharma Inc.	- USD	NaN%
Reve Technologies, Inc.	- USD	NaN%
LadRx Corporation	- USD	NaN%
Cell Source, Inc.	- USD	NaN%
Regen BioPharma, Inc.	236.56 Thousand USD	100.0%
Regen BioPharma, Inc.	236.56 Thousand USD	100.0%
NovAccess Global Inc.	- USD	NaN%
Affymax, Inc.	1.36 Million USD	100.0%
Itoco Inc.	- USD	NaN%
Rasna Therapeutics, Inc.	- USD	NaN%
Pathfinder Cell Therapy, Inc.	- USD	NaN%
Mobile Lads Corp.	- USD	NaN%
CytoDyn Inc.	- USD	NaN%
Claritas Pharmaceuticals, Inc.	- USD	NaN%
NDT Pharmaceuticals Inc.	- USD	NaN%
NanoSphere Health Sciences Inc.	- USD	NaN%
Alseres Pharmaceuticals, Inc.	473.73 Thousand USD	100.0%
SYBLEU INC	11.69 Thousand USD	100.0%
Advanced Proteome Therapeutics Corporation	- USD	NaN%
ImmunoCellular Therapeutics, Ltd.	- USD	NaN%
International Stem Cell Corporation	7.78 Million USD	100.0%
Bioxytran, Inc.	- USD	NaN%
GlobeImmune, Inc.	- USD	NaN%
Predictive Technology Group, Inc.	- USD	NaN%
ProText Mobility, Inc.	- USD	NaN%
Cardax, Inc.	- USD	NaN%
VG Life Sciences Inc.	- USD	NaN%
Kaleido Biosciences, Inc.	- USD	NaN%
Advaxis, Inc.	13 Thousand USD	100.0%
RenovaCare, Inc.	- USD	NaN%
Regnum Corp.	- USD	NaN%
Innovation Pharmaceuticals Inc.	- USD	NaN%
Neutra Corp.	39.53 Thousand USD	100.0%
Windtree Therapeutics, Inc.	- USD	NaN%
PureTech Health plc	3.33 Million USD	100.0%
Coeptis Therapeutics, Inc.	- USD	NaN%
IXICO plc	6.66 Million USD	100.0%
IntelGenx Technologies Corp.	1.03 Million USD	100.0%
Gelesis Holdings, Inc.	25.76 Million USD	100.0%
CSL Limited	14.8 Billion USD	100.0%
Cellectis S.A.	755 Thousand USD	100.0%

Global Stocks Search

Adhera Therapeutics, Inc. (ATRX)

Revenue Summary of Adhera Therapeutics, Inc.

Annual Revenue Chart of Adhera Therapeutics, Inc. (2022 - 1989)

Historical Annual Revenue of Adhera Therapeutics, Inc. (2022 - 1989)

Peer Revenue Comparison of Adhera Therapeutics, Inc.